


THE CLAIMS


A listing of the claims are as follows.

1. (Currently Amended) An anthraquinone compound of the general formula I or a salt thereof



I

in which R¹ is at the 4 position and is selected from the group consisting of H, -NHR⁰N (R⁵)₂ in which R⁰ is a C₁₋₁₂ alkanediyl and each R⁵ is H or optionally substituted C₁₋₄ alkyl, and a group of formula II




(II)

in which at least one of R⁶, R⁷ and R⁸ is selected from X², and X² substituted C₁₋₄ alkyl and any others are H or C₁₋₄ alkyl; R⁹ is selected from H, C₁₋₄ alkyl, X² and X² substituted C₁₋₄ alkyl;

m is 0 or 1;

n is 1 or 2;

R² is at the 1 position and is selected from H, -NHR⁰N (R⁵)₂ in which R⁰ is a C₁₋₁₂ alkanediyl and each R⁵ is H or optionally substituted C₁₋₄ alkyl, and a group of formula II



in which at least one of R^6 , R^7 and R^8 is selected from X^2 , and X^2 substituted C_{1-4} alkyl and any others are H or C_{1-4} alkyl; R^9 is selected from H, C_{1-4} alkyl, X^2 and X^2 substituted C_{1-4} alkyl;

m is 0 or 1;

n is 1 or 2;

R^3 is at the 5 position and is H or OH;

R^4 is at the 8 position and is H or OH;

X^2 is a halogen atom, a hydroxyl group, an aryloxy group or an acyloxy group or another nucleofugal leaving group;

provided that at least one of R^1 or R^2 [[to R^4]] is a group of formula II.

2. (Original) A compound according to claim 1 in which R^1 and R^2 are each a group of formula II.

3. (Original) A compound according to claim 1 in which R^1 is a group of formula II and R^2 is $NHR^5N(R^5)_2$.

4. (Original) A compound according to claim 3 in which each R^5 is the same and is H or CH_3 .

5-6. (Canceled)

7. (Currently Amended) A compound according to claim [[6]] 1 in which R^3 and R^4 are both hydroxyl and are substituted at positions 5 and 8 in the anthraquinone ring system.

8. (Original) A compound according to claim 6 in which R^3 and R^4 are both H.
9. (Previously Presented) A compound according to claim 1, in which m is 1.
10. (Previously Presented) A compound according to claim 1, in which m is 0.
11. (Previously Presented) A compound according to claim 1, in which n is 2.
12. (Currently Amended) A compound according to claim 1, in which X^2 is a halogen atom or a nucleofugal leaving group.
13. (Original) A compound according to claim 12, in which X^2 is chlorine.
14. (Previously Presented) A compound according to claim 1, in which either
- i) R^6 is CH_2X^3 and R^7 is H; or
 - ii) R^6 is H and R^7 is X^3 .
15. (Original) A compound according to claim 14 in which R^6 is CH_2X^3 and R^7 is H.
16. (Original) A compound according to claim 15 in which n is 2 and R^9 is CH_2X^3 in which X^3 is the same as X^3 in R^6 .
17. (Canceled)
18. (Previously Presented) A composition comprising a compound according to claim 9 and an excipient.
19. (Original) A composition according to claim 18 which is a pharmaceutical composition and in which the excipient is a pharmaceutically acceptable excipient.

20-39. (Canceled)

40. (Previously Presented) A composition comprising a compound according to claim 12 and an excipient.

41-43. (Canceled)

44. (Previously Presented) A compound selected from the group consisting of:

1- {[(2-Dimethylamino)ethyl]amino }-4- {[2-(3-hydroxypiperidin-1-yl)ethyl]amino }-anthracene-9,10-dione;

1,4-Bis- {[2-(3-hydroxypiperidin-1-yl)ethyl]-amino }-anthracene-9,10-dione;

1,4-Bis- {[2-(3-hydroxymethylpiperidine-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis- {[2-(3-hydroxymethylpiperidine-1-yl)ethyl]amino }-anthracene-9,10-dione;

1- [(2-Dimethylamino)ethylamino]-4- [2-(3-hydroxymethyl-piperidin-1-yl)ethylamino]-5,8-dihydroxy-anthracene-9,10-dione;

1- [(2-Dimethylamino)ethylamino]-4- [2-(3-hydroxypiperidin-1-yl)-ethylamino]-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis- {[2-(2-hydroxymethylpiperidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[(2-Dimethylamino)ethyl]amino }-4- {[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[(2-Dimethylamino)ethyl]amino }-4- {[2-(4-hydroxypiperidin-1-yl)ethyl]amino }-anthracene-9,10-dione;

1,4-Bis- {[2-(3-hydroxypyrrolidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1,4-Bis- {[2-(4-hydroxypiperidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[(2-Dimethylamino)ethyl]amino }-4- {[2-(4-hydroxypyrrolidin-1-yl)ethyl]amino }-5,8-dihydroxy-anthracene-9,10-dione;

1- {[2-(2-Dimethylamino)ethyl]amino}-4- {[2-(2-hydroxymethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1,4-Bis- {[2-(2-hydroxymethylpyrrolidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2,6-Dihydroxymethylpiperidin-1-yl)ethyl]amino}-4- {[2-(2-Dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and
1- {[2-(2-Hydroxymethylpyrrolidin-1-yl)ethyl]amino}-anthracene-9,10-dione.

45. (Previously Presented) A compound selected from the group consisting of:

1- {[2-(3-Chloropiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(4-Chloropiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2-Chloromethylpyrrolidin-1-yl)ethyl]-amino}-4- {[2-(2-Dimethylamino)ethyl] amino}- 5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(3-Chloropyrrolidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(3-Chloropiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-anthracene-9,10-dione;

1- {[2-(2-Chloromethylpiperidin-1-yl)ethyl]amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2-Chloromethylpiperidin-1-yl)ethyl]-(amino)-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(2,6-Dichloromethylpiperidin-1-yl)ethyl]-amino}-4- {[2-(2-dimethylamino)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1- {[2-(2-chloromethylpyrrolidin-1-yl)ethyl]amino}-anthracene-9,10-dione.

46. (Previously Presented) A compound selected from the group consisting of:

1,4-Bis- {[2-(2-chloromethylpyrrolidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1,4-Bis- {[2-(3-chloromethylpiperidin-1-yl)ethyl]amino}-anthracene-9,10-dione;

1,4-Bis- {[2-(3-chloromethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1,4-Bis- {[2-(2-chloromethylpiperidin-1-yl)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

47. (Previously Presented) The compound:

1- {[2-(2-Hydroxymethylpyrrolidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxy-anthracene-9,10-dione.

48. (Previously Presented) A compound selected from the group consisting of:

1- {[2-(3-Chloropiperidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione;

1- {[2-(4-Chloropiperidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione; and

1- {[2-(2-Chloromethylpyrrolidin-1-yl)-*N*-oxide)ethyl]amino}-4- {[2-(dimethylamino-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

49. (Previously Presented) The compound:

1,4-Bis- {[2-(2-chloromethylpiperidin-1-yl)-*N*-oxide)ethyl]amino}-5,8-dihydroxyanthracene-9,10-dione.

50. (Previously Presented) A composition comprising a compound and an excipient, wherein the compound is according to claim 10.